Home › Funds › Andera Partners › EVMN
Andera Partners position in EVMN
EVOMMUNE INC · Health Care
Andera Partners reported holding 97,362 shares of EVMN (EVOMMUNE INC) in its Q3 2026 13F filing — a position valued at US$804K, representing 0.46% of its reported portfolio and ranking #6 among its reported holdings. Andera Partners has disclosed EVMN holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-10-17 · Source: SEC EDGAR Form 13F-HR
How Andera Partners's EVMN position evolved
Andera Partners first disclosed a stake in EVMN in Q4 2025 at 1,897,362 shares (US$32.5M). The position peaked in Q1 2026 at 1,897,362 shares, worth US$43.6M. Across 4 filings, Andera Partners increased the stake 0 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 97,362 shares valued at US$804K — a reduction of -1,294,628 shares quarter over quarter.. Notable position changes include a 27% trim in Q2 2026 (shares fell 38% over the following quarter), a 93% trim in Q3 2026 (shares fell 19% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 1.90M | $32.48M | New |
| Q1 2026 | 1.90M | $43.62M | Hold |
| Q2 2026 | 1.39M | $18.50M | Reduce |
| Q3 2026 | 97.36K | $804.21K | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About EVMN and 13F data
EVMN (EVOMMUNE INC) is a Health Care company. 116 other funds we track also report a position in EVMN — the largest reported positions include EQT Fund Management S.a r.l. (US$70.3M), RA CAPITAL MANAGEMENT, L.P. (US$46.4M), SymBiosis Capital Partners, LLC (US$29.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding EVMN
- EQT Fund Management S.a r.l. 5.29M sh · $70.28M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 3.49M sh · $46.44M · Q2 2026
- SymBiosis Capital Partners, LLC 1.28M sh · $29.45M · Q1 2026
- Pivotal bioVenture Partners Investment Advisor LLC 1.93M sh · $25.61M · Q2 2026
- Nan Fung Group Holdings Ltd 1.44M sh · $19.15M · Q2 2026
- Defilade Capital Management, L.P. 793.14K sh · $10.54M · Q2 2026
- Velan Capital Investment Management LP 451.25K sh · $6.00M · Q2 2026
- GREAT POINT PARTNERS LLC 325.00K sh · $4.32M · Q2 2026
- Blue Owl Capital Holdings LP 180.00K sh · $2.39M · Q2 2026
- NEXTBio Capital Management LP 119.06K sh · $1.58M · Q2 2026
- Avidity Partners Management LP 75.00K sh · $996.75K · Q2 2026
More on Andera Partners
FAQ
How long has Andera Partners held EVMN?
Andera Partners has disclosed EVMN holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Andera Partners's current position in EVMN?
As of Q3 2026, Andera Partners holds 97.36K shares of EVMN (EVOMMUNE INC), valued at $804.21K, representing 0.46% of its reported portfolio and ranking #6.
Has Andera Partners been buying or selling EVMN?
In the latest 13F filing (Q3 2026), Andera Partners reduced its position in EVMN. The position peaked in Q1 2026 at 1.90M shares.
Which other funds hold EVMN?
Other major institutional holders of EVMN include EQT Fund Management S.a r.l., RA CAPITAL MANAGEMENT, L.P., SymBiosis Capital Partners, LLC, among 116 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.